» Articles » PMID: 16099630

Low Fat Dietary Intervention with Omega-3 Fatty Acid Supplementation in Multiple Sclerosis Patients

Abstract

Objectives: To determine whether a low fat diet supplemented with omega-3 positively affects quality of life (QOL) in relapsing-remitting MS (RRMS) patients. In this 1-year long double-blind, randomized trial, patients were randomized to two dietary interventions: the "Fish Oil" (FO) group received a low fat diet (15% fat) with omega-3 FOs and the "Olive Oil" (OO) group received the AHA Step I diet (fat 30%) with OO supplements. The primary outcome measure was the Physical Components Summary Scale (PCS) of the Short Health Status Questionnaire (SF-36). Additional measures using MS specific QOL questionnaires, neurological status and relapse rate were obtained.

Results: 31 RRMS patients were enrolled, with mean follow up over 11 +/- SD 2.9 months. Clinical benefits favoring the FO group were observed on PCS/SF-36 (P = 0.050) and MHI (P = 0.050) at 6 months. Reduced fatigue was seen on the OO diet at 6 months (P = 0.035). The relapse rate decreased in both groups relative to the rates during the 1 year preceding the study: mean change in relapse rate in the FO group: -0.79 +/- SD 1.12 relapses/year (P = 0.021) vs. -0.69 +/- SD 1.11 (P = 0.044) in the OO group. This study suggests that a low fat diet supplemented with omega-3 PUFA can have moderate benefits in RRMS patients on concurrent disease modifying therapies.

Citing Articles

Thinking outside the brain: Gut microbiome influence on innate immunity within neurodegenerative disease.

Merchak A, Bolen M, Tansey M, Menees K Neurotherapeutics. 2024; 21(6):e00476.

PMID: 39482179 PMC: 11585893. DOI: 10.1016/j.neurot.2024.e00476.


Quality of reporting health behaviors for multiple sclerosis (QuoRH-MS): A scoping review to inform intervention planning and improve consistency of reporting.

Probst Y, Kinnane E Brain Behav. 2024; 14(8):e3635.

PMID: 39148370 PMC: 11327400. DOI: 10.1002/brb3.3635.


Metabolomics of Multiple Sclerosis Lesions Demonstrates Lipid Changes Linked to Alterations in Transcriptomics-Based Cellular Profiles.

Ladakis D, Pedrini E, Reyes-Mantilla M, Sanjayan M, Smith M, Fitzgerald K Neurol Neuroimmunol Neuroinflamm. 2024; 11(3):e200219.

PMID: 38547430 PMC: 11073865. DOI: 10.1212/NXI.0000000000200219.


Association Between Improved Serum Fatty Acid Profiles and Cognitive Function During a Dietary Intervention Trial in Relapsing-Remitting Multiple Sclerosis.

Saxby S, Haas C, Shemirani F, Titcomb T, Ten Eyck P, Rubenstein L Int J MS Care. 2024; 26(2):61-68.

PMID: 38482513 PMC: 10930804. DOI: 10.7224/1537-2073.2023-037.


Blood-based targeted metabolipidomics reveals altered omega fatty acid-derived lipid mediators in relapsing-remitting multiple sclerosis patients.

Zahoor I, Waters J, Ata N, Datta I, Pedersen T, Cerghet M bioRxiv. 2024; .

PMID: 38260401 PMC: 10802284. DOI: 10.1101/2024.01.04.574253.